English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 0/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 4.37%
Price change 2019 → 2020: 537.67%
Price change 2020 → 2021: 58.57%
Price change 2021 → 2022: -47.56%
Price change 2022 → 2023: -39.47%
Price change 2023 → 2024: -79.42%
Price change 2024 → 2025: -58.03%
Price change 2025 → 2026: 35.91%
Price change 2026 (year to date): 40.14%
Financial growth
Revenue CAGR (8 years): 17.22%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 1.90
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -0.20
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 48.41% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ALBIO.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Biosynex S.A. | – | 1.90 | +35.4 % | 🔒 |
| Valbiotis S.A. | – | 0.73 | +56.9 % | – |
| Implanet S.A. | – | 14.66 | +5.0 % | – |
| Aelis Farma S.A. | – | 1.49 | +49.1 % | – |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Biosynex S.A. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 172 m | 35.0 m | 20.4 % | n/a |
| 2021 | 426 m | 116 m | 27.2 % | +148.6 % |
| 2022 | 219 m | 17.5 m | 8.0 % | -48.6 % |
| 2023 | 104 m | -41.2 m | -39.7 % | -52.7 % |
| 2024 | 113 m | -48.3 m | -42.8 % | +8.8 % |
| 2025 | 106 m | -64.9 m | -61.1 % | -5.9 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Biosynex S.A. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 132 m | 87.2 m | 26.2 m | 9.7 m | 8.5 m |
| Total Debt | 35.3 m | 52.1 m | 65.6 m | 62.5 m | 61.6 m |
| Net Debt | -96.7 m | -35.1 m | 45.4 m | 57.8 m | 53.2 m |
| Equity | 168 m | 162 m | 124 m | 80.6 m | 32.4 m |
| Total assets | 269 m | 260 m | 242 m | 195 m | 136 m |
| Operating cash flow | 110 m | 4.9 m | -9.7 m | -10.1 m | -5.9 m |
| Investments (capex) | 19.0 m | 30.1 m | 39.5 m | 4.8 m | 2.7 m |
| Free cash-flow | 90.8 m | -25.1 m | -49.2 m | -15.0 m | -8.6 m |
| Share buybacks | 20.1 m | 1.7 m | 3.2 m | 0 | 0 |
| Dividends paid | 1.9 m | 20.4 m | 0 | 0 | 0 |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Biosynex S.A. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Biosynex S.A. | 17.2 m | n/a | -61.1 % |
| Predilife S.A. ALPRE.PA | 3.7 m | n/a | -315.3 % |
| AMA Corporation Plc ALAMA.PA | 5.4 m | n/a | -285.4 % |
| Euromedis Groupe ALEMG.PA | 18.0 m | n/a | -0.3 % |
| Intrasense S.A. ALINS.PA | 12.1 m | n/a | -364.8 % |
| Mauna Kea Technologies S.A. ALMKT.PA | 21.2 m | n/a | 131.0 % |
| SpineGuard S.A. ALSGD.PA | 9.9 m | n/a | -55.0 % |
| Bluelinea S.A. ALBLU.PA | 2.6 m | n/a | -14.5 % |
| Media Lab S.p.A. MLLAB.PA | 5.8 m | 36.7 | 11.0 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 06/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
Biosynex S.A.: dividend history, last distributions, stock splits and earnings releases.
Annual dividend per share (EUR), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 16/05/2022 | 2.00 EUR | 18/05/2022 |
| 26/05/2021 | 0.200 EUR | 28/05/2021 |
Stock splits
| Date | Operation |
|---|---|
| 02/12/2016 | split: 1,029 shares for 1,000 |
| 22/10/2015 | split: 1,023 shares for 1,000 |
| 04/12/2014 | split: 1,041 shares for 1,000 |
| 23/05/2011 | split: 1,021 shares for 1,000 |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Biosynex S.A.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 01/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Biosynex S.A.
What is the Biosynex S.A. share price?
Latest recorded price: 0.830 EUR on 06/11/2026, for a market cap of 17.1 m USD.
What is the revenue of Biosynex S.A.?
106 m USD for fiscal year 2025, with net income of -64.9 m USD (net margin -61.1 %).
Does Biosynex S.A. pay a dividend?
Yes. Latest dividend: 2.00 EUR per share, ex-dividend on 16/05/2022. Over 12 months: 0.0000 EUR. Yield on the latest known price: 0.0 %.
Is Biosynex S.A. stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN FR0011005933) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does Biosynex S.A. have?
515 full-time employees according to the latest published profile.
Who runs Biosynex S.A.?
Larry Abensur is the company's chief executive.